Índice Bovespa

US Dollar vs BRL

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

ABBV AbbVie Inc

194,205

0,185 (0,10%)

Última atualização: 16:15:45

Atrasado em 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

08/07/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ THOMAS HUDSON

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

AbbVie (NYSE:ABBV)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024

Click aqui para mais gráficos AbbVie.

AbbVie (NYSE:ABBV)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024

Click aqui para mais gráficos AbbVie.

Notícias AbbVie Inc

Allergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China
Quarta, 11 de Setembro de 2024 (2 dias atrás) • PR Newswire (US)

Form 8-K - Current report
Terça, 10 de Setembro de 2024 (3 dias atrás) • Edgar (US Regulatory)

Health Canada Approves AbbVie's CONSTELLA® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients 6 to 17 Years of Age
Terça, 10 de Setembro de 2024 (3 dias atrás) • PR Newswire (Canada)

AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs
Segunda, 9 de Setembro de 2024 (4 dias atrás) • PR Newswire (US)

AbbVie Declares Quarterly Dividend
Sexta, 6 de Setembro de 2024 (1 semana atrás) • PR Newswire (US)

AbbVie reçoit une recommandation favorable de la part de l'Agence des médicaments du Canada pour le remboursement de VRAYLAR® (cariprazine) dans le traitement de la schizophrénie
Quarta, 4 de Setembro de 2024 (1 semana atrás) • PR Newswire (Canada)

AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases
Terça, 27 de Agosto de 2024 (2 semanas atrás) • PR Newswire (US)

SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator
Terça, 27 de Agosto de 2024 (2 semanas atrás) • PR Newswire (US)

European Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Segunda, 19 de Agosto de 2024 (4 semanas atrás) • PR Newswire (US)

AbbVie annonce les premiers remboursements provinciaux, en Ontario et au Québec, d'EPKINLY(MC) (epcoritamab) administré par voie sous-cutanée pour le traitement du lymphome diffus à grandes cellules B en vertu d'un nouveau processus d'accès rapide
Quinta, 15 de Agosto de 2024 (4 semanas atrás) • PR Newswire (Canada)

AbbVie Announces Ontario and Quebec are First Provinces to Reimburse Subcutaneous EPKINLY™ (epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process
Quinta, 15 de Agosto de 2024 (4 semanas atrás) • PR Newswire (Canada)

Form S-8 - Securities to be offered to employees in employee benefit plans
Quarta, 14 de Agosto de 2024 (4 semanas atrás) • Edgar (US Regulatory)

Mais Notícias de AbbVie Inc

Índice Bovespa

MAGAZINE LUIZA ON

TRIUNFO PART ON

PÃO DE AÇUCAR ON

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições